Which has preferable earnings & valuation, AMGN or ABBV?

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $36.75B 5.34 $7.71B $14.37 25.29 AbbVie $61.16B 7.16 $4.23B $2.03 122.17

Is AMGN or ABBV more profitable?

Amgen has a net margin of 20.96% compared to AbbVie's net margin of 5.79%. Amgen's return on equity of 137.41% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Amgen 20.96% 137.41% 13.28% AbbVie 5.79% -576.45% 13.39%

Does the media favor AMGN or ABBV?

In the previous week, AbbVie had 1 more articles in the media than Amgen. MarketBeat recorded 40 mentions for AbbVie and 39 mentions for Amgen. Amgen's average media sentiment score of 1.23 beat AbbVie's score of 0.87 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 26 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 18 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is GILD or ABBV more profitable?

Gilead Sciences has a net margin of 30.99% compared to AbbVie's net margin of 5.79%. Gilead Sciences' return on equity of 48.19% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences 30.99% 48.19% 18.28% AbbVie 5.79% -576.45% 13.39%

Does the media prefer GILD or ABBV?

In the previous week, AbbVie had 2 more articles in the media than Gilead Sciences. MarketBeat recorded 40 mentions for AbbVie and 38 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.00 beat AbbVie's score of 0.87 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 21 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 18 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, MRNA or ABBV?

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 13.93 -$2.82B -$8.15 N/A AbbVie $61.16B 7.16 $4.23B $2.03 122.17

Is MRNA or ABBV more profitable?

AbbVie has a net margin of 5.79% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% AbbVie 5.79% -576.45% 13.39%

Does the media refer more to MRNA or ABBV?

In the previous week, AbbVie had 12 more articles in the media than Moderna. MarketBeat recorded 40 mentions for AbbVie and 28 mentions for Moderna. AbbVie's average media sentiment score of 0.87 beat Moderna's score of 0.74 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 12 Very Positive mention(s) 7 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 18 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABT or ABBV more profitable?

Abbott Laboratories has a net margin of 13.90% compared to AbbVie's net margin of 5.79%. Abbott Laboratories' return on equity of 17.62% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Abbott Laboratories 13.90% 17.62% 10.01% AbbVie 5.79% -576.45% 13.39%

Does the media prefer ABT or ABBV?

In the previous week, AbbVie had 12 more articles in the media than Abbott Laboratories. MarketBeat recorded 40 mentions for AbbVie and 28 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.38 beat AbbVie's score of 0.87 indicating that Abbott Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 21 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 18 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ABBV or AZN?

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $61.16B 7.16 $4.23B $2.03 122.17 Astrazeneca $58.74B 4.54 $10.23B $6.66 25.80

Is ABBV or AZN more profitable?

Astrazeneca has a net margin of 17.19% compared to AbbVie's net margin of 5.79%. Astrazeneca's return on equity of 30.86% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 5.79% -576.45% 13.39% Astrazeneca 17.19% 30.86% 12.68%

Does the media refer more to ABBV or AZN?

In the previous week, AbbVie had 9 more articles in the media than Astrazeneca. MarketBeat recorded 40 mentions for AbbVie and 31 mentions for Astrazeneca. AbbVie's average media sentiment score of 0.87 beat Astrazeneca's score of 0.24 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 18 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 14 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 7 Negative mention(s) 3 Very Negative mention(s) Neutral

AbbVie (ABBV) Competitors

$248.00 -1.91 (-0.76%)

Closing price 07/10/2026 03:59 PM Eastern

Extended Trading

$248.82 +0.82 (+0.33%)

As of 07/10/2026 07:59 PM Eastern

Compare

ABBV vs. AMGN, GILD, MRNA, ABT, and AZN

Should you buy AbbVie stock or one of its competitors? MarketBeat compares AbbVie with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AbbVie include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), and Astrazeneca (AZN).

How does AbbVie compare to Amgen?

Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

In the previous week, AbbVie had 1 more articles in the media than Amgen. MarketBeat recorded 40 mentions for AbbVie and 39 mentions for Amgen. Amgen's average media sentiment score of 1.23 beat AbbVie's score of 0.87 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	26 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	18 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

76.5% of Amgen shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amgen has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Amgen has a net margin of 20.96% compared to AbbVie's net margin of 5.79%. Amgen's return on equity of 137.41% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
AbbVie	5.79%	-576.45%	13.39%

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	5.34	$7.71B	$14.37	25.29
AbbVie	$61.16B	7.16	$4.23B	$2.03	122.17

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.8%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Amgen pays out 70.1% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen currently has a consensus target price of $355.73, suggesting a potential downside of 2.11%. AbbVie has a consensus target price of $262.81, suggesting a potential upside of 5.97%. Given AbbVie's stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84

Summary

AbbVie beats Amgen on 10 of the 19 factors compared between the two stocks.

How does AbbVie compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Gilead Sciences presently has a consensus target price of $159.04, suggesting a potential upside of 22.50%. AbbVie has a consensus target price of $262.81, suggesting a potential upside of 5.97%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	3 Hold rating(s)	26 Buy rating(s)	0 Strong Buy rating(s)	2.90
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84

Gilead Sciences has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Gilead Sciences has a net margin of 30.99% compared to AbbVie's net margin of 5.79%. Gilead Sciences' return on equity of 48.19% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
AbbVie	5.79%	-576.45%	13.39%

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, AbbVie had 2 more articles in the media than Gilead Sciences. MarketBeat recorded 40 mentions for AbbVie and 38 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.00 beat AbbVie's score of 0.87 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	21 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	18 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has raised its dividend for 10 consecutive years and AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has higher earnings, but lower revenue than AbbVie. Gilead Sciences is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.47	$8.51B	$7.34	17.69
AbbVie	$61.16B	7.16	$4.23B	$2.03	122.17

Summary

Gilead Sciences beats AbbVie on 13 of the 20 factors compared between the two stocks.

How does AbbVie compare to Moderna?

Moderna (NASDAQ:MRNA) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

75.3% of Moderna shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, AbbVie had 12 more articles in the media than Moderna. MarketBeat recorded 40 mentions for AbbVie and 28 mentions for Moderna. AbbVie's average media sentiment score of 0.87 beat Moderna's score of 0.74 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	12 Very Positive mention(s)	7 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	18 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	13.93	-$2.82B	-$8.15	N/A
AbbVie	$61.16B	7.16	$4.23B	$2.03	122.17

Moderna currently has a consensus price target of $38.27, indicating a potential downside of 43.95%. AbbVie has a consensus price target of $262.81, indicating a potential upside of 5.97%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84

AbbVie has a net margin of 5.79% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
AbbVie	5.79%	-576.45%	13.39%

Moderna has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Summary

AbbVie beats Moderna on 12 of the 17 factors compared between the two stocks.

How does AbbVie compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, AbbVie had 12 more articles in the media than Abbott Laboratories. MarketBeat recorded 40 mentions for AbbVie and 28 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.38 beat AbbVie's score of 0.87 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	21 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	18 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Abbott Laboratories has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.7%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Abbott Laboratories pays out 70.6% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories has raised its dividend for 54 consecutive years and AbbVie has raised its dividend for 53 consecutive years.

Abbott Laboratories has higher earnings, but lower revenue than AbbVie. Abbott Laboratories is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.69	$6.52B	$3.57	26.32
AbbVie	$61.16B	7.16	$4.23B	$2.03	122.17

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Abbott Laboratories has a net margin of 13.90% compared to AbbVie's net margin of 5.79%. Abbott Laboratories' return on equity of 17.62% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
AbbVie	5.79%	-576.45%	13.39%

Abbott Laboratories presently has a consensus target price of $118.42, suggesting a potential upside of 26.01%. AbbVie has a consensus target price of $262.81, suggesting a potential upside of 5.97%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.93
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84

Summary

Abbott Laboratories beats AbbVie on 14 of the 20 factors compared between the two stocks.

How does AbbVie compare to Astrazeneca?

AbbVie (NYSE:ABBV) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.16	$4.23B	$2.03	122.17
Astrazeneca	$58.74B	4.54	$10.23B	$6.66	25.80

In the previous week, AbbVie had 9 more articles in the media than Astrazeneca. MarketBeat recorded 40 mentions for AbbVie and 31 mentions for Astrazeneca. AbbVie's average media sentiment score of 0.87 beat Astrazeneca's score of 0.24 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	18 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	14 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	7 Negative mention(s)	3 Very Negative mention(s)	Neutral

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.5%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

AbbVie currently has a consensus price target of $262.81, indicating a potential upside of 5.97%. Astrazeneca has a consensus price target of $211.00, indicating a potential upside of 22.78%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts clearly believe Astrazeneca is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Astrazeneca has a net margin of 17.19% compared to AbbVie's net margin of 5.79%. Astrazeneca's return on equity of 30.86% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-576.45%	13.39%
Astrazeneca	17.19%	30.86%	12.68%

AbbVie has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Summary

AbbVie beats Astrazeneca on 13 of the 20 factors compared between the two stocks.

Get AbbVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABBV vs. The Competition

Export

Metric	AbbVie	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$441.54B	$333.45B	$7.12B	$23.43B
Dividend Yield	2.77%	2.68%	2.68%	4.04%
P/E Ratio	122.17	29.70	27.22	31.27
Price / Sales	7.16	5.41	590.16	20.39
Price / Cash	16.50	14.20	49.34	25.05
Price / Book	-135.52	8.37	10.90	4.77
Net Income	$4.23B	$11.61B	$3.57B	$1.07B
7 Day Performance	-4.94%	-2.39%	-0.25%	-0.50%
1 Month Performance	10.20%	7.32%	5.77%	2.09%
1 Year Performance	28.95%	25.70%	28.14%	16.03%

AbbVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABBV AbbVie	4.7491 of 5 stars	$248.00 -0.8%	$262.81 +6.0%	+27.2%	$441.54B	$61.16B	122.17	57,000	Trending News Analyst Forecast
AMGN Amgen	4.1051 of 5 stars	$362.42 -0.3%	$355.73 -1.8%	+21.0%	$195.83B	$36.75B	25.25	31,500	Positive News Analyst Forecast
GILD Gilead Sciences	4.8831 of 5 stars	$131.67 -2.4%	$159.04 +20.8%	+13.3%	$163.52B	$29.44B	17.94	17,000	Positive News Analyst Forecast
MRNA Moderna	2.1829 of 5 stars	$68.53 -10.5%	$38.27 -44.2%	+99.2%	$27.29B	$1.94B	N/A	4,700	Trending News Analyst Forecast Options Volume
ABT Abbott Laboratories	4.9921 of 5 stars	$94.41 +0.0%	$118.42 +25.4%	-29.7%	$164.43B	$44.33B	26.44	115,000	Positive News Upcoming Earnings Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ABBV) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Competitors